|Bid||47.51 x 1200|
|Ask||48.19 x 1800|
|Day's Range||48.13 - 51.28|
|52 Week Range||22.92 - 111.36|
|Beta (3Y Monthly)||3.02|
|PE Ratio (TTM)||8.96|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||89.38|
Wall Street analysts anticipate that Acadia Pharmaceuticals (ACAD) will report net income of -$63.01 million for the third quarter of 2018. It was -$63.3 million in the second quarter, which compares to -$67.4 million in the second quarter of 2017. In the first half of this year, its net income was -$117.66 million. In the first half of 2017, it was -$155.3 million.
In October, ten analysts are covering Nektar Therapeutics (NKTR) stock. Eight of them have given the stock a “buy” or higher rating, and two have given it a “hold.” The mean rating for the stock is 1.8 with a target price of $89.38, implying an upside potential of 82.1% over its closing price of $49.08 on October 15.
Nektar Therapeutics’ (NKTR) cost of goods sold was $5.52 million in the second quarter of 2018 compared to $8.99 million in the second quarter of 2017.
Nektar Therapeutics (NKTR) is focused on developing a strong pipeline of product candidates that utilize its polymer conjugate technology platforms. Its research pipeline includes investigational drugs for cancer, autoimmune diseases, and chronic pain. Nektar Therapeutics generated revenues of $1.09 billion in the second quarter of 2018.
A look at who's moving, who's growing and who's dealing in the Bay Area's health care and life sciences space.
Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“NKTR” or the “Company”) (NASDAQ: NKTR). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. Following publication of the Plainview report, Nektar’s stock price fell $5.63 per share, or 9.24%, over the following two trading sessions, closing at $55.33 per share on October 2, 2018.
In September 2018, the US FDA granted Portola Pharmaceuticals’ cerdulatinib, an investigational Syk/JAK inhibitor, an orphan drug designation for peripheral T-cell lymphoma (or PTCL) therapy. The FDA grants this designation to support the development of therapies for rare diseases. This designation provides benefits such as seven years of market exclusivity after approval, tax credits for certain clinical trials, and exemption of FDA application fees.
Our weekly Health Care Digest gets your week off to a newsy start with Allogene's upsized IPO, a fresh round of capital for an East Bay ag-bio, a new CEO at an inhaled insulin developer and marketing questions for a San Francisco e-cigarette maker.
On CNBC's "Mad Money Lightning Round" , Jim Cramer said instead of Anheuser Busch Inbev NV (NYSE: BUD ), he would buy Constellation Brands (NYSE: STZ ). Cramer would wait for a pullback of 7 ...
DEEP DIVE (This is the third in a three-part series listing the small-cap, midcap and large-cap companies included in the S&P 1500 Composite Index that are expected to show the fastest sales growth in 2018.
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a defense play that he got flak for recommending.
Holzer & Holzer, LLC is investigating whether Nektar Therapeutics complied with the federal securities laws. On October 1, 2018, Plainview LLC published a report raising questions about Nektar’s claims concerning its clinical stage drug, NKTR-214, and its ability to effectively treat cancer.
BOSTON , Oct. 3, 2018 /PRNewswire/ -- Block & Leviton LLP ( www.blockesq.com ), a securities litigation firm representing investors nationwide, is investigating whether Nektar Therapeutics ("Nektar" ...
NEW YORK , Oct. 3, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("NKTR" or the "Company") (NASDAQ: NKTR). Such investors ...
The Dow was the only average to close higher --setting an all-time record -- while the Nasdaq and S&P 500 sat out the action amid lingering trade tensions between the U.S. and China in the wake of Monday's revised trade agreement with Canada and Mexico. As Eric Jhonsa points out: Stitch Fix went into earnings priced for perfection, or close to it. "In that context, Stitch Fix's Tuesday nosedive is perhaps one more cautionary tale about being over-exposed in the current market environment to Internet and software high-flyers that have been bid up to steep multiples.
Here's what you need to know about a report that suggests Bristol invested $1.85 billion into a program worth absolutely nothing.
The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis
SAN FRANCISCO , Oct. 2, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that ten clinical and preclinical data presentations across its immuno-oncology portfolio will be presented ...
NEW YORK, NY / ACCESSWIRE / October 2, 2018 / U.S. equities were mixed on Monday after the U.S. and Canada agreed to revise the current North American Free Trade Agreement. The Dow Jones Industrial Average ...
SAN FRANCISCO, Oct. 1, 2018 /PRNewswire/ -- Nektar Therapeutics (NKTR) today announced that it has appointed Karin Eastham as an independent director to its Board of Directors. Ms. Eastham brings more than 35 years of experience as both an executive and independent director in the biotechnology industry, with particular expertise in finance and operations. Prior to her retirement in 2008, she served as Executive Vice President and Chief Operating Officer and Trustee of the Burnham Institute for Medical Research.
BioXcel Therapeutics, Inc. (“BTI”) (BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, and Nektar Therapeutics (NKTR) announced today that the companies are expanding their ongoing research collaboration into a new clinical partnership.
This analysis is intended to introduce important early concepts to people who are starting to invest and want to begin learning the link between company’s fundamentals and stock market performance.Read More...